Newsletter - View InhalteNewsletter2023

ID	555
Newsletter2023	2023-12-01
Element	10274
Info	[Universal 2023] [Banner] Banner BAK-Fortbildung MS-Therapie mit Teriflunomid (10274)
Position	8
html	<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important"> <tbody> <tr> <td align="center" style="padding:0;Margin:0"> <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center"> <tbody> <tr> <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px"> <tbody> <tr> <td valign="top" align="center" style="padding:0;Margin:0;width:660px"> <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff"> <tbody> <tr> <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/wissen/zertifizierte-fortbildungen/ms-therapie-mit-teriflunomid/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_ZertFobi_MS-Therapie-mit-Teriflunomid.jpg" alt="Zur BAK-Fortbildung MS-Therapie mit Teriflunomid" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Zur BAK-Fortbildung MS-Therapie mit Teriflunomid"></a></td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table> </td> </tr> </tbody> </table>

Newsletter2023

2023-12-01

Info

[Universal 2023] [Banner] Banner BAK-Fortbildung MS-Therapie mit Teriflunomid (10274)

html

<table class="es-content" cellspacing="0" cellpadding="0" align="center" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;width:100%;table-layout:fixed !important">
    <tbody>
        <tr>
            <td align="center" style="padding:0;Margin:0">
                <table style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px;background-color:transparent;width:700px" cellspacing="0" cellpadding="0" align="center">
                    <tbody>
                        <tr>
                            <td align="left" style="padding:0;Margin:0;padding-right:20px;padding-left:20px">
                                <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:collapse;border-spacing:0px">
                                    <tbody>
                                        <tr>
                                            <td valign="top" align="center" style="padding:0;Margin:0;width:660px">
                                                <table width="100%" cellspacing="0" cellpadding="0" style="mso-table-lspace:0pt;mso-table-rspace:0pt;border-collapse:separate;border-spacing:0px;border-radius:0;background-color:#ffffff" bgcolor="#ffffff">
                                                    <tbody>
                                                        <tr>
                                                            <td align="left" class="adapt-img" style="padding:0;Margin:0;font-size:0"><a target="_blank" href="https://www.deutschesapothekenportal.de/wissen/zertifizierte-fortbildungen/ms-therapie-mit-teriflunomid/" style="mso-line-height-rule:exactly;text-decoration:none;font-size:14px;color:#005CA9"><img class="adapt-img" src="https://www.deutschesapothekenportal.de/newsletter/nlbanner/DAP-NL-Banner_ZertFobi_MS-Therapie-mit-Teriflunomid.jpg" alt="Zur BAK-Fortbildung MS-Therapie mit Teriflunomid" style="display:block;font-size:14px;border:0;outline:none;text-decoration:none;border-radius:0" title="Zur BAK-Fortbildung MS-Therapie mit Teriflunomid"></a></td>
                                                        </tr>
                                                    </tbody>
                                                </table>
                                            </td>
                                        </tr>
                                    </tbody>
                                </table>
                            </td>
                        </tr>
                    </tbody>
                </table>
            </td>
        </tr>
    </tbody>
</table>

View InhalteNewsletter2023 #555